NASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free WGS Stock Alerts $27.04 +1.36 (+5.30%) (As of 06/11/2024 ET) Add Compare Share Share Today's Range$24.82▼$27.3750-Day Range$9.05▼$27.2852-Week Range$1.16▼$28.54Volume296,581 shsAverage Volume386,097 shsMarket Capitalization$706.28 millionP/E RatioN/ADividend YieldN/APrice Target$18.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get GeneDx alerts: Email Address GeneDx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside30.7% Downside$18.75 Price TargetShort InterestBearish7.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 14 Articles This WeekInsider TradingAcquiring Shares$3.77 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.48 out of 5 starsMedical Sector844th out of 905 stocksHealth Services Industry10th out of 10 stocks 1.3 Analyst's Opinion Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGeneDx has only been the subject of 4 research reports in the past 90 days.Read more about GeneDx's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.16% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeneDx has recently increased by 0.86%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for WGS. Previous Next 2.0 News and Social Media Coverage News SentimentGeneDx has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for GeneDx this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for WGS on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have bought 1,090.70% more of their company's stock than they have sold. Specifically, they have bought $3,771,670.00 in company stock and sold $316,761.00 in company stock.Percentage Held by Insiders28.10% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GeneDx's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GeneDx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years. See His Breakdown of the Seven Stocks You Should Own Here. About GeneDx Stock (NASDAQ:WGS)GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.Read More WGS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WGS Stock News HeadlinesJune 6, 2024 | insidertrades.comGeneDx Holdings Corp. (NASDAQ:WGS) Director Purchases $2,082,000.00 in StockMay 29, 2024 | insidertrades.comInsider Buying: GeneDx Holdings Corp. (NASDAQ:WGS) Director Purchases 7,500 Shares of StockMay 16, 2024 | insidertrades.comCasdin Capital, Llc Acquires 50,000 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) StockJune 10 at 8:30 AM | globenewswire.comGeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal PatientsJune 7, 2024 | americanbankingnews.comGeneDx (NASDAQ:WGS) Reaches New 12-Month High on Insider Buying ActivityJune 7, 2024 | americanbankingnews.comCasdin Capital, Llc Acquires 100,000 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) StockJune 6, 2024 | seekingalpha.comGeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic TestingJune 5, 2024 | globenewswire.comGeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy PatientsJune 5, 2024 | americanbankingnews.comGeneDx (NASDAQ:WGS) Receives New Coverage from Analysts at Jefferies Financial GroupJune 2, 2024 | 247wallst.comInsider Buying Heats Up at Fracker, Aircraft and Boat Makers, and MoreMay 29, 2024 | msn.comOver $4M Bet On ProFrac Holding? Check Out These 3 Stocks Insiders Are BuyingMay 22, 2024 | globenewswire.comGeneDx to Participate in Upcoming Investor ConferencesMay 2, 2024 | finance.yahoo.comGeneDx Holdings Corp. (NASDAQ:WGS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesApril 30, 2024 | finanznachrichten.deGeneDx Holdings Corp.: GeneDx Reports First Quarter 2024 Financial Results and Business HighlightsApril 30, 2024 | markets.businessinsider.comGeneDx is about to announce its earnings — here's what to expectApril 30, 2024 | finance.yahoo.comGeneDx Holdings Corp (WGS) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues and ...April 29, 2024 | msn.comWGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q1 2024April 29, 2024 | msn.comGeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 GuidanceApril 29, 2024 | finance.yahoo.comGeneDx Holdings Corp (WGS) Q1 2024 Earnings: Surpasses Revenue Expectations and Narrows LossesApril 29, 2024 | msn.comGeneDx reports Q1 resultsApril 29, 2024 | globenewswire.comGeneDx Reports First Quarter 2024 Financial Results and Business HighlightsApril 28, 2024 | msn.comGeneDx Q1 2024 Earnings PreviewApril 27, 2024 | finance.yahoo.comGeneDx Holdings Corp. (WGS)April 23, 2024 | finance.yahoo.comGeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease DatasetApril 23, 2024 | globenewswire.comGeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease DatasetSee More Headlines Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/29/2024Today6/11/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryN/A Current SymbolNASDAQ:WGS CUSIPN/A CIK1818331 Websema4.com Phone800-298-6470FaxN/AEmployees1,000Year FoundedN/APrice Target and Rating Average Stock Price Target$18.75 High Stock Price Target$24.00 Low Stock Price Target$11.00 Potential Upside/Downside-30.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($5.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-175,770,000.00 Net Margins-60.86% Pretax Margin-61.25% Return on Equity-36.23% Return on Assets-20.92% Debt Debt-to-Equity Ratio0.25 Current Ratio3.22 Quick Ratio2.99 Sales & Book Value Annual Sales$202.57 million Price / Sales3.49 Cash FlowN/A Price / Cash FlowN/A Book Value$8.78 per share Price / Book3.08Miscellaneous Outstanding Shares26,120,000Free Float18,782,000Market Cap$706.28 million OptionableOptionable Beta2.21 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMs. Katherine A. Stueland (Age 48)President, CEO & Director Comp: $745.91kMr. Kevin Feeley (Age 43)Chief Financial Officer Comp: $488.19kMs. Karen PonchnerSenior VP & Head of OperationsMr. Eric Olivares Ph.D.Chief Product & Technology OfficerMr. Devin K. Schaffer J.D.M.B.A., General CounselMr. Paul Kruszka M.D.Chief Medical OfficerMs. Melanie DuquetteChief Growth OfficerSabrina DunbarChief of StaffMore ExecutivesKey CompetitorsLifeStance Health GroupNASDAQ:LFSTPrivia Health GroupNASDAQ:PRVAU.S. Physical TherapyNYSE:USPHThe Pennant GroupNASDAQ:PNTGInnovAgeNASDAQ:INNVView All CompetitorsInsiders & InstitutionsKatherine StuelandSold 2,652 sharesTotal: $66,087.84 ($24.92/share)Kevin FeeleySold 895 sharesTotal: $22,303.40 ($24.92/share)Casdin Capital, LlcBought 100,000 shares on 6/3/2024Total: $2.08 M ($20.82/share)Casdin Capital, LlcBought 18,304 shares on 5/28/2024Total: $377,245.44 ($20.61/share)Casdin Capital, LlcBought 7,500 shares on 5/23/2024Total: $146,925.00 ($19.59/share)View All Insider TransactionsView All Institutional Transactions WGS Stock Analysis - Frequently Asked Questions Should I buy or sell GeneDx stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GeneDx in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" WGS shares. View WGS analyst ratings or view top-rated stocks. What is GeneDx's stock price target for 2024? 4 Wall Street analysts have issued 1-year price objectives for GeneDx's shares. Their WGS share price targets range from $11.00 to $24.00. On average, they predict the company's stock price to reach $18.75 in the next twelve months. This suggests that the stock has a possible downside of 30.7%. View analysts price targets for WGS or view top-rated stocks among Wall Street analysts. How have WGS shares performed in 2024? GeneDx's stock was trading at $2.75 at the beginning of the year. Since then, WGS stock has increased by 883.3% and is now trading at $27.04. View the best growth stocks for 2024 here. When is GeneDx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our WGS earnings forecast. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) released its quarterly earnings results on Monday, April, 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.68) by $0.35. The company earned $62.42 million during the quarter, compared to analyst estimates of $49.80 million. GeneDx had a negative net margin of 60.86% and a negative trailing twelve-month return on equity of 36.23%. When did GeneDx's stock split? GeneDx's stock reverse split on Thursday, May 4th 2023. The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What guidance has GeneDx issued on next quarter's earnings? GeneDx updated its FY 2024 earnings guidance on Monday, April, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $235.0 million-$245.0 million, compared to the consensus revenue estimate of $226.1 million. Who are GeneDx's major shareholders? GeneDx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Oracle Investment Management Inc. (4.31%), Vanguard Group Inc. (2.71%), Gagnon Securities LLC (2.13%), Gagnon Advisors LLC (0.81%), Jacobs Levy Equity Management Inc. (0.77%) and Thompson Davis & CO. Inc. (0.09%). Insiders that own company stock include Anthony Prentice, Casdin Capital, Llc, Daniel Emmett Clark, Eric Schadt, Isaac Ro, James Coffin, Jason Ryan, Kareem Saad, Karen Ann White, Katherine Stueland, Keith A Meister, Kevin Feeley, Richard C Pfenniger Jr, Richard Miao, Shawn Assad and Tactical Opportunit Blackstone. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:WGS) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.